← Leaderboards
Joseph J Cullen
University Of Iowa
$5,964,157
Attributed
$5,964,157
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.9M · FY2006–22$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$15,586,323 · 8
VA$0 · 1
By mechanism
P01$12,802,796 · 3
R01$1,391,087 · 1
R21$666,399 · 2
K08$376,596 · 1
U01$349,445 · 1
I01$0 · 1
Top collaborators
- Douglas Robert Spitz5 shared
Most similar at University Of Iowa
Same institution · by research overlap
- Garry R Buettner$6,434,018
- Bryan Allen$2,697,856
- Melissa Ann Fath$775,635
- Kelly Hubert$162,164
- James Donald Byrne$2,110,857
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMalignant NeoplasmsCancer CellProgramsHydrogen PeroxideCancer TherapyOxidative StressMetabolismNeoplastic CellMalignant Neoplasm Of PancreasCytotoxicityFoundationsIn VitroClinical TrialsGemcitabineReportingBaseNormal CellMediatingOxidation-ReductionCombined Cancer Modality TherapyAscorbic AcidAscorbateCessation Of Life
Grant awards (33)
Exploiting Redox Metabolism Using Pharmacological Ascorbate for Cancer Therapy$1,910,960
P01 · FY2022 · CA · contact PI
Project 1: Inhibition of Metastasis Utilizing Pharmacological Ascorbate in Pancreas Cancer$502,555
P01 · FY2022 · CA · contact PI
Administrative Core - Core A$133,090
P01 · FY2022 · CA · contact PI
Exploiting Redox Metabolism Using Pharmacological Ascorbate for Cancer Therapy$1,943,218
P01 · FY2021 · CA · contact PI
Project 1: Inhibition of Metastasis Utilizing Pharmacological Ascorbate in Pancreas Cancer$509,053
P01 · FY2021 · CA · contact PI
Administrative Core - Core A$132,850
P01 · FY2021 · CA · contact PI
Exploiting Redox Metabolism Using Pharmacological Ascorbate for Cancer Therapy$1,943,218
P01 · FY2020 · CA · contact PI
Project 1: Inhibition of Metastasis Utilizing Pharmacological Ascorbate in Pancreas Cancer$509,053
P01 · FY2020 · CA · contact PI
Administrative Core - Core A$132,850
P01 · FY2020 · CA · contact PI
Exploiting Redox Metabolism Using Pharmacological Ascorbate for Cancer Therapy$1,884,922
P01 · FY2019 · CA · contact PI
Project 1: Inhibition of Metastasis Utilizing Pharmacological Ascorbate in Pancreas Cancer$493,783
P01 · FY2019 · CA · contact PI
Administrative Core - Core A$128,863
P01 · FY2019 · CA · contact PI
Exploiting Redox Metabolism Using Pharmacological Ascorbate for Cancer Therapy$1,939,848
P01 · FY2018 · CA · contact PI
Project 1: Inhibition of Metastasis Utilizing Pharmacological Ascorbate in Pancreas Cancer$509,053
P01 · FY2018 · CA · contact PI
Pharmacological Ascorbate as a Radiosensitizer in Pancreatic Cancer$348,844
R01 · FY2018 · CA · contact PI
Administrative Core - Core A$129,480
P01 · FY2018 · CA · contact PI
Mechanisms of pharmacological ascorbate inhibition of pancreatic cancer metastases$0
I01 · FY2018 · VA · contact PI
Pharmacological Ascorbate as a Radiosensitizer in Pancreatic Cancer$348,844
R01 · FY2017 · CA · contact PI
Pharmacological Ascorbate as a Radiosensitizer in Pancreatic Cancer$347,986
R01 · FY2016 · CA · contact PI
Role of HIF-1 alpha in EcSOD-Induced Growth Inhibition of Pancreatic Cancer$0
I01 · FY2016 · VA · contact PI
Pharmacological Ascorbate as a Radiosensitizer in Pancreatic Cancer$345,413
R01 · FY2015 · CA · contact PI
Role of HIF-1 alpha in EcSOD-Induced Growth Inhibition of Pancreatic Cancer$0
I01 · FY2015 · VA · contact PI
Role of HIF-1 alpha in EcSOD-Induced Growth Inhibition of Pancreatic Cancer$0
I01 · FY2014 · VA · contact PI
ASCORBATE-INDUCED RADIOSENSITIZATION IN PANCREATIC CANCER$185,232
U01 · FY2013 · CA · contact PI
Role of HIF-1 alpha in EcSOD-Induced Growth Inhibition of Pancreatic Cancer$0
I01 · FY2013 · VA · contact PI
ASCORBATE-INDUCED RADIOSENSITIZATION IN PANCREATIC CANCER$164,213
U01 · FY2012 · CA · contact PI
Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer$198,000
R21 · FY2010 · CA · contact PI
Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer$165,000
R21 · FY2009 · CA · contact PI
Mechanisms of Dicumarol-Induced Cytotoxicity$163,274
R21 · FY2007 · CA · contact PI
Mechanisms of Dicumarol-Induced Cytotoxicity$140,125
R21 · FY2006 · CA · contact PI
Mechanistic Role of Peroxynitrite in Gallbladder Disease$125,172
K08 · FY2004 · DK
Mechanistic Role of Peroxynitrite in Gallbladder Disease$126,252
K08 · FY2003 · DK
Mechanistic Role of Peroxynitrite in Gallbladder Disease$125,172
K08 · FY2002 · DK